FCR-HM101-100μg / 询价
FCR-HM101-500μg / 询价
FCR-HM101-500μgx2 / 询价
表达区间及表达系统(Source)
|
Recombinant Human FcRH5/FcRL5 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln16-Gly851 [Accession | Q96RD9-1]. |
分子量大小(Molecular Weight)
|
The protein has a predicted MW of 92.38 kDa. Due to glycosylation, the protein migrates to 120-140 kDa based on Bis-Tris PAGE result. |
纯度(Purity)
|
>95% as determined by Bis-Tris PAGE |
内毒素(Endotoxin)
|
Less than 1 EU per μg by the LAL method. |
制剂(Formulation)
|
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
重构方法(Reconstitution)
|
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
存储(Storage)
|
-20 to -80°C for 12 months as supplied from date of receipt. |
Recombinant Human FcRH5/FcRL5 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln16-Gly851 [Accession | Q96RD9-1].
The protein has a predicted MW of 92.38 kDa. Due to glycosylation, the protein migrates to 120-140 kDa based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2
(1) Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163.MCT-12-0087.
FCR-HM101-100μg / 询价
FCR-HM101-500μg / 询价
FCR-HM101-500μgx2 / 询价
货号* | 规格* | 名称 | 数量* | |
---|---|---|---|---|
货号* | 名称 | 批号* | |
---|---|---|---|